top of page
 divarasib: A KRAS G12C inhibitor being evaluated in clinical studies
 divarasib: A KRAS G12C inhibitor being evaluated in clinical studies

Wed, Nov 29

|

Webinar

divarasib: A KRAS G12C inhibitor being evaluated in clinical studies

Join us for an informational presentation provided by our partners at Roche / Genentech.

Registration is closed
See other events

Time & Location

Nov 29, 2023, 12:00 PM – 1:00 PM EST

Webinar

About the Event

On Wednesday, November 29th, KRAS KICKERS will host an informational presentation given by Roche/Genentech titiled, divarasib: A KRAS G12C inhibitor being evaluated in clinical studies. The presentation will begin at 9:00am PST / 12:00pm EST/ 6:00pm CET. A link to join this event will be included in a follow-up email for those who RSVP to the event. There will be an opportunity for Q&A. 

An event for this link will be shared once registration is completed here.

More About This Event

Objectives include:

  • An Introduction to KRAS G12C and divarasib

  • Presentation of clinical data from ongoing Phase 1 study of divarasib

Share This Event

This website is not intended to, and does not, provide medical advice, professional diagnosis, opinion, treatment, or services. Medical information provided on this site is for informational and educational purposes only. After reading content from this website, you are encouraged to review the information carefully with your physician.

© 2025 KRAS Cancer Connect. All rights reserved.    Nonprofit EIN 85-4372947 

bottom of page